Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke. by Cavendish, Jeffrey J et al.
UC Irvine
UC Irvine Previously Published Works
Title
Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke.
Permalink
https://escholarship.org/uc/item/1r01p8jk
Journal
Current medical research and opinion, 20(11)
ISSN
0300-7995
Authors
Cavendish, Jeffrey J
Cramer, Steven C
Graham, Glenn D
Publication Date
2004-11-01
DOI
10.1185/030079904x10674
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ORIGINAL ARTICLE: SUPPLEMENT
Role of antiplatelet therapy 
in cardiovascular disease II:
Ischemic stroke
Jeffrey J. Cavendish1, Steven C. Cramer2 and 
Glenn D. Graham3
1Department of Cardiology, Naval Medical Center, San Diego, CA, USA
2Departments Neurology and Anatomy and Neurobiology, UCI Medical Center,
University of California Irvine, Orange, CA, USA
3Departments of Neurology, Radiology, and Neurosciences, Albuquerque
VA and Neurology/127, VA Medical Center, University of New Mexico
School of Medicine, Albuquerque, NM, USA
Address for correspondence: Dr Jeffrey J. Cavendish, Department of Cardiology, Building 3, 
3rd Floor, Naval Medical Center, San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, USA.
Tel.: +1-619-532-7421; Fax: +1-619-532-9863; email: JJCavendish@nmcsd.med.navy.mil
Key words: Antiplatelet – Atherothrombosis – Ischemic stroke – Transient ischemic attack
Paper 2728B 1845
CURRENT MEDICAL RESEARCH AND OPINION®
VOL. 20, NO. 11, 2004, 1845–1849
© 2004 LIBRAPHARM LIMITED
0300-7995
doi:10.1185/030079904X10674
Introduction
Cerebrovascular disease is the third leading cause of
mortality in the United States – accounting for over
163 000 deaths in 2001 – and the leading cause of
serious, long-term disability1. Nearly one in every 14
deaths in the United States is due to stroke, with an
average of one stroke fatality every 3 min. The
prevalence of stroke is about 4.8 million, with
approximately 700 000 new or recurrent cases each
year1. The financial impact of stroke is high, with the
direct and indirect cost of stroke in 2004 predicted to
be US$54 billion1.
The pathogenesis of cerebrovascular disease is
heterogeneous: 80–85% of all strokes are of ischemic
origin, caused by obstruction of the cerebral vasculature,
while the remaining 15–20% are hemorrhagic1–3. 
The most common underlying etiology of ischemic
stroke results from atherothrombotic processes leading
to narrowing or blockage of arteries. Large-artery
atherothrombosis accounts for 20–30%, microatheroma
and other small-artery occlusive disease (‘lacunar’
stroke) for 20–25%, and cardiogenic embolism for
15–20% of all ischemic strokes. The remaining causes
are of other (5%) or cryptogenic (30%) etiology3.
Thrombotic and embolic strokes may be preceded by
a transient ischemic attack (TIA), a mild and transitory
event now recognized as an important precursor and
long-term risk factor for stroke and other vascular
ischemic accidents4,5. In the 90 days after a TIA, there is
a 25% overall risk of an adverse event, including
recurrent TIA (13%), stroke (11%), cardiovascular
hospitalization (3%) or death (3%)6. More than half of
these adverse events occur in the first 2 days after TIA.
treatments focus on secondary prevention through
risk-factor management, pharmacotherapy and
interventional approaches. As illustrated in this
paper, antiplatelet agents (e.g. clopidogrel, aspirin,
dipyridamole) are the cornerstone of therapy for
prevention of recurrent ischemic stroke.
S U M M A R Y
The etiology of cerebrovascular disease is 
heterogeneous, with the majority of strokes being 
of ischemic origin. Transient ischemic attack is 
now considered to be an important precursor and 
long-term risk factor for ischemic stroke. Given the 
lack of acute therapies for ischemic stroke, current
Depending on the vascular bed affected, the
atherothrombotic disease process can also manifest as
acute coronary syndromes or peripheral arterial disease7.
Consistent with the generalized nature of
atherothrombosis, 30–50% of stroke and TIA patients
have a history of coronary artery disease8–10. Because of
this atherothrombotic cross-risk, stroke and TIA patients
are not only at an increased risk of stroke, but also other
ischemic vascular events, particularly myocardial
infarction11,12. Indeed, over the 10-year period after a first
ischemic stroke, the risk of death from cardiovascular
events is double that from recurrent stroke12.
Considering the substantial mortality, morbidity and
economic cost of stroke, there is a clear need for
improved strategies to prevent new and recurrent stroke.
Existing approaches include lifestyle modifications and
management of risk factors (e.g. hypertension,
hyperlipidemia, obesity, smoking), pharmacotherapy, and
interventional approaches (e.g. endarterectomy, carotid
stenting). Several important pharmacologic therapies can
be considered, including treatment with anticoagulants
(particularly in patients with atrial fibrillation), HMG-
CoA reductase inhibitors (statins; particularly in coronary
artery disease patients with elevated cholesterol) and
antiplatelet agents.
As the majority of all strokes are ischemic in etiology,
most stroke patients are suitable candidates for
antiplatelet therapy, the benefits of which have been
firmly established13. Aspirin remains the mainstay of
antithrombotic therapy for the secondary prevention of
stroke, reducing the relative risk of stroke recurrence by
13–18%3,8,14. Further benefits may be realized when low-
dose aspirin is combined with extended-release
dipyridamole (37% relative risk reduction vs placebo)8.
Studies have demonstrated that the ADP receptor
antagonist clopidogrel effectively prevents secondary
stroke. In the CAPRIE study involving 19 185 patients
with recent ischemic stroke, myocardial infarction or
peripheral arterial disease, there was a significant
advantage of clopidogrel over aspirin, based on a 8.7%
relative risk reduction ( p = 0.043) in the composite
endpoint of ischemic stroke, myocardial infarction or
vascular death9. In CAPRIE, the average yearly risk of
this composite endpoint was 5.32% with clopidogrel and
5.83% with aspirin. This advantage is amplified in
patients with a history of ischemic events15. Results of
the recently completed MATCH study16 confirm the
benefit of clopidogrel monotherapy in high-risk ischemic
stroke/TIA patients17; however, in this high-risk
population, adding aspirin to a baseline therapy of
clopidogrel increased the rate of serious bleeding without
significantly improving efficacy18.
The following collection of case studies is the second
of a three-part set illustrating the role of antiplatelet
therapy in current treatment strategies for various
manifestations of atherothrombosis. The topic of the
case reports presented in this article is ischemic stroke,
with case reports on acute coronary syndromes19 and
peripheral arterial disease20 presented in the
accompanying articles.
Case studies
1. Cryptogenic Stroke in a Healthy 
40-Year-Old Woman
A 40-year-old woman presented with right arm and leg
heaviness and numbness of 1 days duration. For the
previous 2 months she had noticed intermittent,
isolated right hand ‘tingling’ that occurred only during
exercise and abated shortly after stopping, but she had
not sought medical attention. However, for the past day,
she had also noted numbness of the leg and arm that
began while she was at rest.
The patient was generally in good health, and her past
medical history was limited to recurrent sinus infections.
She was told at the age of 16 years that she had a heart
murmur, but no additional testing was performed, and
this has not been mentioned during subsequent medical
checkups. She previously smoked one pack of cigarettes
per day for 8 years, but quit 10 years ago. She regularly
consumed 1–2 glasses of wine with dinner.
At presentation, her vital signs were: blood pressure
119/72 mmHg; pulse 71 beats/min and regular;
respirations 18 breaths/min; and temperature 37.6 °C.
General physical examination was unremarkable, with no
carotid bruits or cardiac murmurs. On neurological
examination, the patient was alert with normal speech and
recall. The fundoscopic exam was normal. Cranial nerves
2–12 were intact, without facial asymmetry or sensory
loss. Muscle strength was 5/5 throughout (Medical
Research Council scale), with normal muscle bulk and
tone. Coordination in the arms and legs was intact. There
was a subjective dulling of touch and pin sensation in the
right upper and lower extremities, but position sense was
preserved in the hands and feet. Reflexes were 2+
throughout and plantar response was flexor bilaterally.
Routine laboratory parameters were within normal
limits, and the electrocardiogram showed normal sinus
rhythm. However, head computed tomography (CT)
revealed a lucency in the left parietal region.
The patient was hospitalized for further testing.
Magnetic resonance imaging (MRI) including diffusion-
weighted and fluid-attenuated inversion recovery 
(FLAIR) sequences confirmed an acute left parietal
ischemic stroke, while magnetic resonance angiography of
the circle of Willis and carotid arteries was normal.
Carotid ultrasound revealed very mild, hemodynamically
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insignificant stenosis on both sides. A hypercoagulability
screen was negative. The transesophageal echocardiogram
identified a patent foramen ovale (PFO) with spontaneous
left to right shunting, and documented right to left
shunting on a bubble study with cough. The ejection
fraction was 65%, and no atrial septal aneurysm or other
abnormality was identified. Doppler ultrasound of the legs
revealed no deep venous thrombosis.
The clinical significance of a small PFO is
controversial, and the optimal treatment of patients
with small PFO, stroke, and emboli of unknown source
is uncertain21. Possible treatments options include
closure of the PFO by an open surgical procedure or
with an endovascular closure device, anticoagulation,
and antiplatelet therapy. After discussions between the
cardiology and neurology consultants, it was decided to
use aggressive antiplatelet therapy with clopidogrel
75mg daily and aspirin 81mg daily. This choice satisfied
the patient’s desire to avoid invasive procedures or
chronic warfarin therapy. The patient was started on the
antiplatelet combination prior to hospital discharge and
has subsequently remained free of recurrent events or
any complications of therapy.
2. Multiple Procedures to Prevent Stroke
in a 53-Year-Old Man
A 53-year-old man, well known to our department, with a
long history of atherosclerotic coronary, cerebrovascular
and peripheral vascular disease presented after undergoing
a routine follow-up Doppler ultrasound of his carotid
arteries. Three years prior to this presentation, he had
developed classic symptoms of amaurosis fugax in the left
eye, despite being on aspirin. Severe bilateral internal
carotid artery stenoses were discovered and he underwent
left carotid endarterectomy. Post-operatively he had
severe chest pain, nausea, vomiting and developed a left
cervical nerve injury. He therefore refused surgery on the
stenosis in the right internal carotid artery and opted for
carotid stenting. The patient had also undergone multiple
coronary angioplasty procedures and renal artery stenting
for severe bilateral renal artery stenosis, which was causing
severe renovascular hypertension. The patient had been
doing quite well for the past 3 years on chronic aspirin and
clopidogrel; he had also been taking atenolol, lisinopril,
nicotinic acid, and clonidine.
The carotid ultrasound showed severely elevated
velocities in the left internal carotid artery: the peak
velocity was 499 cm/sec and the left common carotid
velocity was 75cm/sec. Estimated stenosis severity in the
left internal carotid artery was greater than 90%. 
The right carotid stent had normal velocities. The patient
was referred for angiography.
Aortic arch angiography and selective carotid
angiography revealed 90% stenosis in the proximal left
internal carotid artery at the distal margin of the
endarterectomy site (Figure 1a). Carotid angioplasty and
stenting was then performed. A 3000 unit heparin bolus
was given intravenously; the patient continued to take
aspirin and clopidogrel, including on the morning of the
procedure. The stenosis was initially dilated with a
4.0 × 30 mm Opensail balloon (Guidant, Temecula, CA),
and an 8.0 × 30 mm SMART Stent (Cordis, Miami, FL)
was deployed and post-dilated with a 5.5 × 40 mm 
Savvy balloon (Cordis). Post-procedure angiography
demonstrated an excellent result (Figure 1b). In the
absence of any change in baseline neurologic findings after
overnight monitoring, the patient was discharged the next
day on indefinite aspirin (325 mg) and clopidogrel (75 mg)
therapy, in addition to his other outpatient medications.
At his 6-month follow-up exam, the patient continued
to do well with no further episodes of amaurosis fugax.
The patient remains on an aggressive medical regimen 
for risk factor reduction with lifelong aspirin and
clopidogrel, as well as atorvastatin, nicotinic acid,
atenolol and fosinopril.
3. Ischemic Infarct in a 68-Year-Old Man
A 68-year-old man presented to the emergency room
with left arm and leg weakness of 9 hours duration. He
had no history of stroke or TIA. That morning, he had
felt ‘funny’ while shaving, and thought that his face was
possibly drooping when he looked in the mirror. He also
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Figure 1. Selective carotid angiograms illustrating near
complete (90%) stenosis in the proximal left internal carotid
artery (depicted by the white arrow) before (a) and after 
(b) carotid angioplasty and stenting
noted clumsiness when using his left hand to apply the
shaving cream. Shortly thereafter, his left arm and leg
grew weaker. He sat and watched television for most of
the day; by dinner time, his weakness was substantial
and the paramedics were phoned.
The patient’s medical history was remarkable for
peptic ulcer disease, which had been symptomatic 
10 days previously, and he was taking lansoprazole 30mg
daily. The patient had hypertension of 8 years duration,
for which he was treated with hydrochlorothiazide
25 mg/day. The patient had no drug allergies. On the
evening of admission, the patient’s blood pressure was
188/92 mmHg, his pulse was 80 beats/min and regular,
and he was afebrile. General medical examination was
unremarkable. On neurological examination, the patient
had mild-moderate left hemispatial neglect. Language
and attention were unremarkable. Cranial nerve
examination disclosed no gaze preference and mild left
facial weakness. Mild copper wiring was present
bilaterally on fundoscopic examination. The left arm
and leg were 2/5 proximally and distally, though with
prompting, but strength was closer to 4–/5 on the
Medical Research Council scale. Sensory examination
showed no deficits apart from extinction to double
simultaneous stimulation on the face and dorsum of the
hand. Reflex testing was unremarkable, as was cerebellar
examination; no gait examination was performed.
On admission, the patient’s blood chemistry,
complete blood count, and activated partial
thromboplastin time were unremarkable. Total blood
cholesterol was 196 mg/dL (5.1 mmol/L), with low
density lipoprotein = 84 mg/dL (2.2 mmol/L) and high
density lipoprotein = 46 mg/dL (1.3 mmol/L). The
electrocardiogram showed voltage criteria suggestive of
left ventricular hypertrophy. Cranial CT showed early
edema in the right frontoparietal cortex/subcortical
white matter of the middle cerebral artery territory,
which was confirmed by subsequent diffusion-weighted
MRI. Doppler studies identified no significant
intracranial or extracranial cerebral artery disease.
Transesophageal echocardiography revealed slight wall
thickening without other abnormalities apart from a
moderate patent foramen ovale, which was
demonstrated by performing the Valsalva maneuver
after injection of agitated saline contrast medium into
the antecubital vein.
Blood pressure returned to normal on day 3 of
admission. Due to the history of peptic ulcer disease and
risk of gastrointestinal bleeding, the patient was placed
on clopidogrel 75 mg monotherapy once daily for
secondary stroke prevention. On day 4 of admission, the
patient was transferred to an acute rehabilitation ward.
Steady gains were seen in the patient’s motor function
over the subsequent 9 weeks, and in his attentional
examination over the subsequent 12 months. At 1-year
follow-up exam, there was no evidence of any further
arterial events. The patient is scheduled to be on
clopidogrel indefinitely.
Conclusions
The goals of treatment after ischemic stroke or TIA are
multifaceted. In the short term, objectives are to treat
stroke symptoms, to re-establish blood flow and to
restrict brain damage. However, acute therapies for
ischemic stroke are limited: tissue plasminogen activator
is the only approved agent in North America, but the
short 3 h post-stroke therapeutic window and bleeding
concerns effectively restrict its use to 1.6–3% of
patients22,23. Research into other treatment strategies
such as neuroprotection or neurorestoration is ongoing.
For the long-term treatment of ischemic stroke, goals
are to reduce the risks of recurrent stroke and of
ischemic events at other vascular sites. This can be
achieved by identification and treatment of modifiable
risk factors through life-style changes and
pharmacologic intervention. As stroke and TIA patients
are at long-term risk of future ischemic episodes,
antiplatelet therapy is desirable in ischemic stroke
patients. Antiplatelet drugs target not only the
thrombosis responsible for the ischemic cerebrovascular
event, but also the common underlying pathophysiology
of atherothrombosis that increases the risk of ischemic
events in other vascular beds.
The American College of Chest Physicians’ 2004
Guidelines3 recommend antiplatelet therapy to reduce
the risk of secondary stroke and other ischemic events
following an ischemic stroke or TIA. Treatment with
aspirin (50-325 mg) once daily, low-dose aspirin (25
mg) plus extended-release dipyridamole (200 mg) twice
daily, or clopidogrel (75 mg) once daily are acceptable
initial therapies.
Two of the case studies presented here illustrate the
safety and efficacy of clopidogrel plus aspirin dual
therapy. It is appropriate to mention that these patients
were treated before the results of MATCH17 were
available. While MATCH in general does not support
the routine use of clopidogrel plus aspirin combination
in the high-risk stroke patients investigated in the trial,
the patients in the first two case reports fall outside the
MATCH population16,17. The patient in case study 1 had
a presumed (or at least possible) cardiogenic event and
did not exhibit any of the MATCH inclusion criteria
regarding risk factors (e.g. diabetes, prior ischemic
stroke, prior myocardial infarction, angina pectoris, or
symptomatic peripheral arterial disease)16,17. In case
study 2, the patient had not suffered from prior
ischemic stroke or TIA. Therefore, combination therapy
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with clopidogrel plus aspirin may be appropriate for
some patients, although clinicians must weigh the
clinical benefits against the potential increased risk of
bleeding complications.
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